(A) mTOR mRNA expression in TET21N cells measured by RNA-Seq, , mean and SEM. No significant difference in mTOR expression between high-MYCN control and MYCN-inhibited cells with paired t-test, . (B) MYCN protein expression in TET21N neuroblastoma cells under various experimental conditions, measured by flow cytometry, , representative experiment shown. (C and D) Data and model fit of the two replicate experiments not shown in Figure 4C,D. Data shown in black and model fits in blue (MYCN-inhibited) and pink (rapamycin-treated). (C) Distribution of cycle lengths showing median and interquartile range (D) Correlation pattern with bootstrapp 95%-confidence bounds. (E) Model simulated cell size distribution of population at one point in time comparable to Figure 4B. (F) Proportion of simulated MYCN-inhibited and rapamycin-treated cells limited by growth or progression using the growth-progression model showing mean of 100 simulations. Data and model fit of the two replicates not shown in Figure 4F. (G) Evidences relative to model V (as in Figure 2—figure supplement 1A) but for MYCN-inhibited cells. (I) Corresponding correlations. The simpler correlation structure without long-range lateral correlation favors model VII for both replicates -myc1 and -myc2. (H, J) as (G, I) but for rapamycin-treated cells. Strong intra-generational correlations favor model IV and V and exclude model VII. Model III (independent processes) explains only the replicate rap1, shown leftmost in H and in J.